scholarly journals Sunitinib Use for Metastatic Renal Cell Carcinoma Associated with Necrotizing Cavitary Pulmonary Aspergillosis with Aspergillus flavus: Case Report and Review of Literature

Author(s):  
Suganthini Krishnan Natesan

Sunitinib associated chronic necrotizing cavitary pulmonary aspergillosis has rarely been reported in literature. This article describes a patient with biopsy proven papillary renal cell carcinoma initially treated by radical nephrectomy. He presented about 8 months later with progressively worsening abdominal pain, headache, weight loss of 40 pounds and investigation revealed extensive retroperitoneal and mediastinal lymphadenopathy with brain metastasis. He was evaluated by oncology and started on cycles of sunitinib with dexamethasone, which he took for about 6+ months. He presented to the hospital in respiratory distress requiring intubation and ICU admission and CT scan of thorax revealed a new large consolidation with necrosis and a cavity. Given suspicion of opportunistic fungal infection with sunitinib, he was started on empiric Vancomycin, Zosyn and Voriconazole. He underwent bronchoscopy, bronchoalveolar lavage and cultures revealed Aspergillus flavus. Subsequently serum and BAL (Bronchoalveolar Lavage) galactomannan were reported positive as well. Given poor prognosis, patient’s family elected for comfort measures.

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fei Meng ◽  
Luojin Zhang ◽  
Mingjun Zhang ◽  
Kaiqin Ye ◽  
Wei Guo ◽  
...  

Abstract Background BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. Methods Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. Results BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. Conclusions Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma.


Sign in / Sign up

Export Citation Format

Share Document